Physician profile
Robert G Sheets
NPI 1659363315
$4,605.53
in general payments reported to CMS, 2019-2025
17 companies · $493 in 2025
The $493 reported for 2025 was more than what 77% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,651 · 2020: $102 · 2021: $419 · 2022: $787 · 2023: $733 · 2024: $421 · 2025: $493.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,647.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,646.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $1,948.98 | 2019-2025 | Acuvue |
| Bausch & Lomb Americas INC. | $641.09 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Abbvie INC. | $500.37 | 2022-2025 | Vuity, Lumigan |
| Alcon Vision LLC | $288.85 | 2019-2025 | Total30 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $236.98 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $229.54 | 2020-2023 | |
| Sun Pharmaceutical Industries INC. | $199.82 | 2021-2025 | Cequa |
| Sight Sciences, INC. | $109.60 | 2022 | |
| Allergan, INC. | $95.19 | 2020-2022 | |
| Aerie Pharmaceuticals, INC. | $80.08 | 2019 | |
| Coopervision INC. | $71.78 | 2019 | |
| Astellas Pharma US INC | $56.19 | 2023 | |
| Oyster Point Pharma, INC. | $49.63 | 2022-2023 | Tyrvaya |
| Dompe US, INC. | $38.02 | 2021-2025 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $26.47 | 2024 | Xdemvy |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $19.87 | 2023 | Tepezza |
| Kala Pharmaceuticals, INC. | $13.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Sheets listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.